IL148719A0 - Kinase inhibitors as therapeutic agents - Google Patents

Kinase inhibitors as therapeutic agents

Info

Publication number
IL148719A0
IL148719A0 IL14871900A IL14871900A IL148719A0 IL 148719 A0 IL148719 A0 IL 148719A0 IL 14871900 A IL14871900 A IL 14871900A IL 14871900 A IL14871900 A IL 14871900A IL 148719 A0 IL148719 A0 IL 148719A0
Authority
IL
Israel
Prior art keywords
therapeutic agents
kinase inhibitors
kinase
inhibitors
therapeutic
Prior art date
Application number
IL14871900A
Other languages
English (en)
Original Assignee
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22552056&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL148719(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg
Publication of IL148719A0 publication Critical patent/IL148719A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • AIDS & HIV (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL14871900A 1999-09-17 2000-09-15 Kinase inhibitors as therapeutic agents IL148719A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15461899P 1999-09-17 1999-09-17
PCT/US2000/025357 WO2001019828A2 (en) 1999-09-17 2000-09-15 Kinase inhibitors as therapeutic agents

Publications (1)

Publication Number Publication Date
IL148719A0 true IL148719A0 (en) 2002-09-12

Family

ID=22552056

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14871900A IL148719A0 (en) 1999-09-17 2000-09-15 Kinase inhibitors as therapeutic agents

Country Status (27)

Country Link
EP (1) EP1268481B1 (cs)
JP (1) JP2003509427A (cs)
KR (1) KR20020063854A (cs)
CN (1) CN1390220A (cs)
AR (1) AR029766A1 (cs)
AT (1) ATE380814T1 (cs)
AU (1) AU7491400A (cs)
BG (1) BG106585A (cs)
BR (1) BR0014075A (cs)
CA (1) CA2385769A1 (cs)
CY (1) CY1107886T1 (cs)
CZ (1) CZ2002934A3 (cs)
DE (1) DE60037455T2 (cs)
DK (1) DK1268481T3 (cs)
ES (1) ES2299434T3 (cs)
HK (1) HK1053831A1 (cs)
HU (1) HUP0303363A2 (cs)
IL (1) IL148719A0 (cs)
MX (1) MXPA02002938A (cs)
NO (1) NO20021329L (cs)
NZ (1) NZ517759A (cs)
PL (1) PL354241A1 (cs)
PT (1) PT1268481E (cs)
SK (1) SK3792002A3 (cs)
TR (1) TR200201506T2 (cs)
WO (1) WO2001019828A2 (cs)
ZA (1) ZA200202122B (cs)

Families Citing this family (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
JP4524072B2 (ja) 2000-10-23 2010-08-11 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 新規化合物
JP2005508904A (ja) * 2001-09-11 2005-04-07 スミスクライン ビーチャム コーポレーション 血管新生阻害剤としてのフロ−及びチエノピリミジン誘導体
US20050171094A1 (en) * 2002-02-22 2005-08-04 Kenichiro Kataoka Pyrrolopyrimidine derivatives
US7560552B2 (en) 2002-03-21 2009-07-14 Abbott Laboratories Thiopyrimidine and isothiazolopyrimidine kinase inhibitors
US20030225273A1 (en) * 2002-03-21 2003-12-04 Michaelides Michael R. Thiopyrimidine and isothiazolopyrimidine kinase inhibitors
US7629350B2 (en) 2002-04-19 2009-12-08 Smithkline Beecham Corporation Compounds
AU2003246972A1 (en) 2002-08-06 2004-02-23 Astrazeneca Ab Condensed pyridines and pyrimidines with tie2 (tek) activity
JP2006528685A (ja) * 2003-05-06 2006-12-21 スミスクライン ビーチャム コーポレーション 新規化合物
US7297709B2 (en) 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
US7129260B2 (en) 2003-06-02 2006-10-31 Abbott Laboratories Isoindolinone kinase inhibitors
US7202363B2 (en) 2003-07-24 2007-04-10 Abbott Laboratories Thienopyridine and furopyridine kinase inhibitors
US20050026944A1 (en) * 2003-07-24 2005-02-03 Patrick Betschmann Thienopyridine and furopyridine kinase inhibitors
MXPA06001098A (es) * 2003-07-29 2006-04-24 Irm Llc Compuestos y composiciones utiles como inhibidores de proteina cinasa.
CA2548326A1 (en) * 2003-12-23 2005-07-14 Novartis Ag Bicyclic heterocyclic p-38 kinase inhibitors
TW200530236A (en) * 2004-02-23 2005-09-16 Chugai Pharmaceutical Co Ltd Heteroaryl phenylurea
US20070275954A1 (en) * 2004-05-19 2007-11-29 Astrazeneca Ab Novel Fused Heterocycles and Uses Thereof
FR2871158A1 (fr) 2004-06-04 2005-12-09 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
US20070054916A1 (en) * 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
ATE554087T1 (de) * 2004-10-29 2012-05-15 Abbott Lab Neue kinaseinhibitoren
DE102004061288A1 (de) * 2004-12-14 2006-06-29 Schering Ag 3-Amino-Pyrazolo[3,4b]pyridine als Inhibitoren von Proteintyrosinkinasen, deren Herstellung und Verwendung als Arzneimittel
PE20061119A1 (es) 2005-01-19 2006-11-27 Aventis Pharma Sa PIRAZOLO PIRIDINAS SUSTITUIDAS COMO INHIBIDORES DE CINASAS FAK, KDR Y Tie
US7842809B2 (en) 2005-01-24 2010-11-30 Bayer Schering Pharma Ag Pyrazolopyridines and salts thereof, a pharmaceutical composition comprising said compounds, a method of preparing same and use of same
EP1683796A1 (en) * 2005-01-24 2006-07-26 Schering Aktiengesellschaft Pyrazolopyridines, their preparation and their medical use
PE20100741A1 (es) 2005-03-25 2010-11-25 Glaxo Group Ltd COMPUESTOS DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2(1H)-ONA COMO INHIBIDORES DE QUINASA p38
EA200702073A1 (ru) 2005-03-25 2008-12-30 Глэксо Груп Лимитед Способ получения пиридо[2,3-d]пиримидин-7-оновых и 3,4-дигидропиримидо[4,5-d]пиримидин-2(1н)-оновых производных
US20090137550A1 (en) 2005-03-25 2009-05-28 Glaxo Group Limited Novel Compounds
AR053346A1 (es) 2005-03-25 2007-05-02 Glaxo Group Ltd Compuesto derivado de 8h -pirido (2,3-d) pirimidin -7 ona 2,4,8- trisustituida composicion farmaceutica y uso para preparar una composicion para tratamiento y profilxis de una enfermedad mediada por la quinasa csbp/ rk/p38
US7884109B2 (en) 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
US7795248B2 (en) 2005-05-18 2010-09-14 Abbott Laboratories, Inc. Substituted 7,8-dihydro-1H-pyrimido[4,5-B][1,4]diazepin-4-amines are novel kinase inhibitors
FR2889526B1 (fr) * 2005-08-04 2012-02-17 Aventis Pharma Sa 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
DE102005042742A1 (de) * 2005-09-02 2007-03-08 Schering Ag Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
CA2622725A1 (en) * 2005-09-14 2007-03-22 Janssen Pharmaceutica N.V. 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase
TW200800983A (en) * 2005-09-14 2008-01-01 Janssen Pharmaceutica Nv 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of C-FMS kinase
KR20080078668A (ko) 2005-11-17 2008-08-27 오에스아이 파마슈티컬스, 인코포레이티드 융합된 바이사이클릭 ｍＴＯＲ 억제자
EP1957485B1 (en) * 2005-12-02 2013-02-13 Bayer HealthCare, LLC Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
PE20070855A1 (es) * 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
EP1981890A2 (en) * 2006-01-25 2008-10-22 OSI Pharmaceuticals, Inc. UNSATURATED mTOR INHIBITORS
TW200804389A (en) 2006-02-14 2008-01-16 Vertex Pharma Dihydrodiazepines useful as inhibitors of protein kinases
US7989459B2 (en) 2006-02-17 2011-08-02 Pharmacopeia, Llc Purinones and 1H-imidazopyridinones as PKC-theta inhibitors
EP1987037A2 (en) * 2006-02-23 2008-11-05 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
TW200815437A (en) * 2006-06-13 2008-04-01 Bayer Schering Pharma Ag Substituted aminopyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
WO2008022060A2 (en) * 2006-08-14 2008-02-21 Novartis Ag Imidazo-pyridine derivatives for modulating protein kinase activity
US7897762B2 (en) 2006-09-14 2011-03-01 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of proliferative diseases
AR063141A1 (es) 2006-10-04 2008-12-30 Pharmacopeia Inc Derivados de 2- ( benzimidazolil ) purina 8- sustituida para inmunosupresion
US7919490B2 (en) 2006-10-04 2011-04-05 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
US7902187B2 (en) 2006-10-04 2011-03-08 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
ES2371832T3 (es) * 2007-03-22 2012-01-10 Takeda Pharmaceutical Company Limited Pirimidodiazepinas sustituidas útiles como inhibidores de plk1.
WO2008143674A1 (en) 2007-05-23 2008-11-27 Pharmacopeia, Inc. Purinones and 1h-imidazopyridinones as pkc-theta inhibitors
DE102007024470A1 (de) 2007-05-24 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Neue Sulfoximin-substituierte Chinolin- bzw. Chinazolinderivate als Kinase-Inhibitoren
KR20140097440A (ko) 2007-09-25 2014-08-06 다케다 야쿠힌 고교 가부시키가이샤 폴로형 키나아제 억제제
EP2072502A1 (de) 2007-12-20 2009-06-24 Bayer Schering Pharma Aktiengesellschaft Sulfoximid-substituierte Chinolin- und Chinazolinderivate als Kinase-Inhibitoren
CN101239978A (zh) * 2008-03-05 2008-08-13 南方医科大学 一种咪唑并吡啶类化合物
US20100048914A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal Cyp17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
CA2719134C (en) 2008-03-21 2015-06-30 The University Of Chicago Treatment with opioid antagonists and mtor inhibitors
EP2303889A1 (en) 2008-06-18 2011-04-06 F. Hoffmann-La Roche AG Halo-substituted pyrimidodiazepines as plkl inhibitors
CA2743592A1 (en) 2008-12-05 2010-06-10 Abbott Laboratories Thienopyridine kinase inhibitors with improved cyp safety profile
EP3023433A1 (en) 2009-02-05 2016-05-25 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
EP2464647B1 (en) * 2009-08-11 2016-09-21 Bristol-Myers Squibb Company Azaindazoles as btk kinase modulators and use thereof
CA2773827A1 (en) 2009-09-25 2011-03-31 Vertex Pharmaceuticals Incorporated Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors
EP2480550B1 (en) 2009-09-25 2016-02-10 Vertex Pharmaceuticals Incorporated Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors
WO2011095556A1 (en) * 2010-02-08 2011-08-11 N.V. Organon 8-methyl-1-phenyl-imidazol[1,5-a]pyrazine compounds
EP3590938B1 (en) 2010-05-31 2023-05-24 ONO Pharmaceutical Co., Ltd. Purinone derivative as btk kinase inhibitor
AU2015202128B2 (en) * 2010-05-31 2015-05-28 Ono Pharmaceutical Co., Ltd. Purinone derivative
SMT202100729T1 (it) 2011-07-19 2022-01-10 Merck Sharp & Dohme 4-imidazopiridazin-1-il-benzammidi e 4-imidazotriazin-1-ilbenzammidi come inibitori di btk
EP2548877A1 (en) 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
WO2013012909A1 (en) 2011-07-20 2013-01-24 Abbott Laboratories Kinase inhibitor with improved aqueous solubility
CN103958513B (zh) * 2011-11-29 2015-12-23 小野药品工业株式会社 6-羟基嘌呤衍生物盐酸盐
ES2570862T3 (es) 2011-12-15 2016-05-20 Bayer Ip Gmbh Benzotienil-pirrolotriazinas sustituidas y usos de las mismas en el tratamiento de cáncer
UY34484A (es) 2011-12-15 2013-07-31 Bayer Ip Gmbh Benzotienilo-pirrolotriazinas disustituidas y sus usos
US8501724B1 (en) * 2012-01-31 2013-08-06 Pharmacyclics, Inc. Purinone compounds as kinase inhibitors
CA2865021C (en) 2012-02-23 2020-06-30 Bayer Intellectual Property Gmbh Substituted benzothienyl-pyrrolotriazines and uses thereof
CA2874211A1 (en) 2012-05-31 2013-12-05 Pharmascience Inc. Protein kinase inhibitors
CA2782774A1 (en) * 2012-07-06 2014-01-06 Pharmascience Inc. Protein kinase inhibitors
CN103655566B (zh) * 2012-09-10 2016-12-21 杨子娇 化合物在制备防治青光眼病的药物中的用途
CN105796569A (zh) * 2012-09-10 2016-07-27 杨子娇 化合物在制备防治青光眼病的药物中的用途
EP2948458B1 (en) 2013-01-23 2019-05-01 Merck Sharp & Dohme Corp. Btk inhibitors
WO2014113942A1 (en) 2013-01-23 2014-07-31 Merck Sharp & Dohme Corp. Btk inhibitors
AU2014236135A1 (en) 2013-03-14 2015-09-10 Thomas Jefferson University Androgen receptor down-regulating agents and uses thereof
WO2015002894A1 (en) * 2013-07-02 2015-01-08 Pharmacyclics, Inc. Purinone compounds as kinase inhibitors
BR112016002970A2 (pt) 2013-08-12 2017-09-12 Tokai Pharmaceuticals Inc biomarcadores para o tratamento de distúrbios neoplásicos que usa terapias direcionadas ao androgênio
CA2833701A1 (en) * 2013-11-19 2015-05-19 Pharmascience Inc. Protein kinase inhibitors
CA2833867A1 (en) * 2013-11-21 2015-05-21 Pharmascience Inc. Protein kinase inhibitors
BR112016012794A2 (pt) 2013-12-05 2017-08-08 Acerta Pharma Bv Combinação terapêutica de um inibidor de pi3k e um inibidor de btk
US9834554B2 (en) 2013-12-20 2017-12-05 Merck Sharp & Dohme Corp. BTK inhibitors
US9637486B2 (en) 2013-12-20 2017-05-02 Merck Sharp & Dohme Corp. Btk inhibitors
EP3094314B1 (en) 2014-01-16 2021-06-23 MUSC Foundation For Research Development Targeted nanocarriers for the administration of immunosuppressive agents
US10272083B2 (en) 2014-01-21 2019-04-30 Acerta Pharma B.V. Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
WO2015146159A1 (en) 2014-03-25 2015-10-01 Ono Pharmaceutical Co., Ltd. Prophylactic agent and/or therapeutic agent for diffuse large b-cell lymphoma
WO2015181633A2 (en) 2014-04-11 2015-12-03 Acerta Pharma B.V. Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bruton's tyrosine kinase
WO2015193740A2 (en) 2014-06-17 2015-12-23 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor and/or a jak-2 inhibitor
SI3179991T1 (sl) 2014-08-11 2022-04-29 Acerta Pharma B.V. Terapevtske kombinacije zaviralca BTK in zaviralca BCL-2
WO2016106626A1 (en) 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Imidazopyrazine analogs with 3-tertiary carbon substitutions as btk inhibitors
WO2016106623A1 (en) 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Benzamide imidazopyrazine btk inhibitors
WO2016106629A1 (en) 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Btk inhibitors
WO2016106624A1 (en) 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Tertiary alcohol imidazopyrazine btk inhibitors
WO2016106628A1 (en) 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Btk inhibitors
ES2955554T3 (es) 2015-04-09 2023-12-04 Ono Pharmaceutical Co Proceso para producir un derivado de purinona
MX2020014163A (es) 2015-07-02 2022-09-29 Acerta Pharma Bv Formas solidas y formulaciones de (s)-4-(8-amino-3-(1-(but-2-inoil )pirrolidin-2-il)imidazo [1,5-a]pirazin-1-il)-n-(piridin-2-il)benz amida.
CN105130932B (zh) * 2015-07-14 2017-06-16 中国科学院微生物研究所 化合物及其在制备ptp1b抑制剂和治疗和/或预防ⅱ型糖尿病的药物的用途
US10053465B2 (en) 2015-08-26 2018-08-21 Incyte Corporation Pyrrolopyrimidine derivatives as TAM inhibitors
IL261957B (en) 2016-03-28 2022-07-01 Incyte Corp Pyrrolotriazine compounds as tam inhibitors
EP3510032B1 (en) 2016-09-09 2022-07-06 Incyte Corporation Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
US10280164B2 (en) 2016-09-09 2019-05-07 Incyte Corporation Pyrazolopyridone compounds and uses thereof
US20180072741A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyrimidine compounds and uses thereof
WO2018049214A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
US20180228786A1 (en) 2017-02-15 2018-08-16 Incyte Corporation Pyrazolopyridine compounds and uses thereof
WO2019051199A1 (en) 2017-09-08 2019-03-14 Incyte Corporation 6-CYANO-INDAZOLE COMPOUNDS AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) MODULATORS
PT3687996T (pt) 2017-09-27 2022-01-21 Incyte Corp Sais de derivados de pirrolotriazina úteis como inibidores de tam
WO2019164846A1 (en) 2018-02-20 2019-08-29 Incyte Corporation N-(phenyl)-2-(phenyl)pyrimidine-4-carboxamide derivatives and related compounds as hpk1 inhibitors for treating cancer
US10752635B2 (en) 2018-02-20 2020-08-25 Incyte Corporation Indazole compounds and uses thereof
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
AR117600A1 (es) 2018-06-29 2021-08-18 Incyte Corp Formulaciones de un inhibidor de axl / mer
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
EP3856348B1 (en) 2018-09-25 2024-01-03 Incyte Corporation Pyrazolo[4,3-d]pyrimidine compounds as alk2 and/or fgfr modulators
US11066394B2 (en) 2019-08-06 2021-07-20 Incyte Corporation Solid forms of an HPK1 inhibitor
CN115697343A (zh) 2020-03-06 2023-02-03 因赛特公司 包含axl/mer和pd-1/pd-l1抑制剂的组合疗法
WO2024240088A1 (en) * 2023-05-19 2024-11-28 Chengdu Anticancer Bioscience , Ltd. Compounds, compositions and methods of treating disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0001507A3 (en) * 1997-03-19 2002-01-28 Abbott Gmbh & Co Kg Pyrrolo [2,3-d] pyrimidine derivatives, process for their preparation, their use and pharmaceutical compositions containing them
UA71945C2 (en) * 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents

Also Published As

Publication number Publication date
JP2003509427A (ja) 2003-03-11
DE60037455D1 (de) 2008-01-24
CA2385769A1 (en) 2001-03-22
KR20020063854A (ko) 2002-08-05
PL354241A1 (en) 2003-12-29
EP1268481A2 (en) 2003-01-02
PT1268481E (pt) 2008-03-19
TR200201506T2 (tr) 2002-10-21
NO20021329L (no) 2002-05-21
HK1053831A1 (zh) 2003-11-07
BR0014075A (pt) 2002-07-16
WO2001019828A2 (en) 2001-03-22
WO2001019828A3 (en) 2001-10-04
AR029766A1 (es) 2003-07-16
CY1107886T1 (el) 2013-06-19
BG106585A (en) 2003-03-31
EP1268481B1 (en) 2007-12-12
CZ2002934A3 (cs) 2002-07-17
SK3792002A3 (en) 2003-09-11
HUP0303363A2 (hu) 2004-07-28
CN1390220A (zh) 2003-01-08
ATE380814T1 (de) 2007-12-15
ZA200202122B (en) 2003-08-27
AU7491400A (en) 2001-04-17
DK1268481T3 (da) 2008-05-05
DE60037455T2 (de) 2008-11-27
ES2299434T3 (es) 2008-06-01
MXPA02002938A (es) 2004-12-06
NZ517759A (en) 2004-04-30
NO20021329D0 (no) 2002-03-18

Similar Documents

Publication Publication Date Title
IL148719A0 (en) Kinase inhibitors as therapeutic agents
HUP0202713A3 (en) Pteridinones as kinase inhibitors
GB9900416D0 (en) Inhibitors
GB9911863D0 (en) Therapeutic agents
GB9905010D0 (en) Therapeutic agents
IL150030A0 (en) Therapeutic agents
GB9904786D0 (en) Therapeutic agents
GB9929685D0 (en) Therapeutic agents
GB9929687D0 (en) Therapeutic agents
GB9921351D0 (en) Therapeutic agents
GB9911881D0 (en) Therapeutic agents
GB9903476D0 (en) Therapeutic agents
EP1153022A4 (en) PROTEASE INHIBITORS
GB9929569D0 (en) Therapeutic agents
GB9914744D0 (en) Therapeutic agents
GB9914745D0 (en) Therapeutic agents
GB9900222D0 (en) Therapeutic compounds
GB9903119D0 (en) Therapeutic agents
IL147078A0 (en) Therapeutic agents
GB9902881D0 (en) Therapeutic agents
SI1268481T1 (sl) Inhibitorji kinaze kot zdravila
GB9914743D0 (en) Therapeutic agents
GB9915616D0 (en) Therapeutic agents
GB9918057D0 (en) Therapeutic agents
GB9915617D0 (en) Therapeutic agents